Choosing a Veterinary Compounding Partner: What Clinics Should Look For

Veterinary medicine often requires more flexibility than standard prescription products can provide. A patient may need a very specific strength, a different dosage form, a flavor that improves acceptance, or a route of administration that makes treatment more practical for the pet and caregiver.

That is where a dependable veterinary compounding partner can support your clinic.

The right partner does more than fill prescriptions. It helps your team improve medication compliance, manage chronic-care patients, maintain appropriate office stock, and communicate clearly about quality and regulatory requirements.

Start with the clinical needs of your patients

Compounding may be useful when an FDA-approved, conditionally approved, or indexed product is not appropriate for a specific animal. The FDA identifies several practical reasons a veterinarian may choose a compounded preparation, including:

• A dose or concentration that is not commercially available
• A liquid formulation for a patient that cannot be safely pilled
• Flavoring to encourage administration
• A dosage form that better fits the animal or caregiver
• Removal of an inactive ingredient that may be unsuitable for a particular patient
• A different route of administration, when clinically appropriate

For chronic conditions, these details can have a meaningful effect on whether treatment is given consistently.

A veterinary compounding partner should be able to work with your prescribing team on practical options such as:

• Customized capsules, tablets, or lower-volume doses
• Flavored oral liquids
• Chewable medications
• Transdermal gels, when appropriate for the medication and patient
• Combination formulations when clinically justified
• Preparations for small, large, geriatric, or special-needs animals

Compounding is not a replacement for an approved product when that product is medically appropriate. Instead, it is a tool that can help veterinarians address patient-specific needs when a standard product does not provide the right solution.

Understand GFI #256 and the August 2026 draft GFI #256B

Regulatory knowledge should be one of the first things you evaluate in a compounding partner.

The FDA’s final GFI #256 describes circumstances in which the agency generally does not intend to take enforcement action related to animal drugs compounded from bulk drug substances.

GFI #256 covers situations including:

• Patient-specific prescriptions for nonfood-producing animals
• Certain office-stock medications for nonfood-producing animals
• Antidotes for food-producing animals
• Sedatives and anesthetics for free-ranging wildlife

For patient-specific prescriptions, the veterinarian must determine that compounding is medically appropriate. If the compounded preparation is considered a copy of an approved or indexed product, the veterinarian must provide a clinical rationale explaining the difference that makes the compounded preparation appropriate for the identified patient.

A clinical rationale may relate to dose size, flavor, dosage form, an allergy or sensitivity to an ingredient, or another patient-specific concern. Cost or convenience alone is generally not an adequate medical rationale.

Office stock requires additional care. Under GFI #256, office-stock products compounded from bulk drug substances for nonfood-producing animals should use substances included on FDA’s applicable list or list of nominated substances under review. The medication must also meet other conditions, including appropriate labeling, supervision, state-law compliance, and reporting requirements.

In August 2026, the FDA issued draft GFI #256B, addressing compounding animal drugs from bulk drug substances under current good manufacturing practice in federally registered facilities. The draft focuses on facilities such as federally registered 503B outsourcing facilities and certain 510(b) manufacturers.

This draft guidance is important for clinics considering larger-volume or non-patient-specific supply arrangements. However, it is still draft guidance. It does not mean that every 503B facility or veterinary-labeled product is automatically approved or covered. Clinics should confirm the facility’s registration, CGMP controls, product documentation, and alignment with the final regulatory requirements once the guidance is finalized.

For state-licensed pharmacies, GFI #256 remains the key federal guidance for the situations it addresses. A compounding pharmacy should be able to explain which framework applies to a prescription or office-stock request and what documentation the clinic should maintain.

Look for meaningful quality controls

A pharmacy’s quality program should be easy to understand and supported by documentation. Ask potential partners how they manage nonsterile and sterile preparations, ingredients, testing, labeling, and beyond-use dating.

PCAB accreditation

PCAB accreditation is a voluntary third-party quality indicator for compounding pharmacies. It can show that a pharmacy has undergone an external review of its policies, procedures, documentation, and quality systems.

When evaluating accreditation, ask:

• Is the accreditation current?
• Which location and services does it cover?
• Does it include nonsterile, sterile, or hazardous compounding?
• Can the pharmacy explain how its accreditation supports the preparations your clinic orders?

You can learn more about PCAB through ACHC’s PCAB compounding pharmacy resources.

Accreditation should not be the only factor in your decision, but it can be a useful part of a broader quality review.

USP <795> and USP <797>

For nonsterile preparations, ask how the pharmacy follows the principles of USP <795>.

For sterile preparations, ask how the pharmacy follows USP <797>, including controls related to:

• Personnel training and competency
• Cleanroom and primary engineering control certification
• Environmental monitoring
• Sterility testing
• Endotoxin testing, when applicable
• Media-fill and process controls
• Deviation investigation and corrective action

The FDA notes that USP <795> and <797> are not independently binding federal requirements for animal drug compounding under GFI #256, although some states may require compliance. Even when not specifically required by federal guidance, these chapters are important quality benchmarks for responsible pharmacy operations.

Ask about ingredient sourcing and third-party testing

A reliable partner should be able to explain where active pharmaceutical ingredients and excipients come from.

Ask whether ingredients are sourced from licensed and appropriately registered suppliers. You should also be able to request information such as:

• Ingredient identity and lot numbers
• Supplier qualification procedures
• Expiration or retest dates
• Storage and handling requirements
• Certificates of Analysis for incoming ingredients
• Procedures for investigating questionable or rejected materials

For batch-prepared or higher-risk products, ask whether the pharmacy uses independent, third-party testing. Depending on the preparation, testing may include potency, identity, sterility, endotoxins, uniformity, or other relevant quality attributes.

A Certificate of Analysis, or COA, should provide useful batch-level information rather than serving as a generic form. Ask what the COA covers, who performed the testing, and whether the results correspond to the exact lot dispensed to your clinic.

Verify stability testing and beyond-use dating

Beyond-use dates should be supported by appropriate data and professional judgment. This is especially important for medications kept as office stock, because the product may remain in inventory before it is administered.

Ask your compounding partner:

• Is the formulation supported by stability data?
• Were real-time or accelerated studies performed?
• What storage conditions were evaluated?
• How are potency and degradation monitored?
• What happens if a preparation changes color, texture, odor, or appearance?
• Are storage instructions clearly stated on the label?

For sterile products, also ask how sterility and container-closure considerations are addressed.

A pharmacy that cannot clearly explain its beyond-use dating process may not be prepared to support the quality needs of a veterinary clinic.

Evaluate communication and operational support

Quality is not only about what happens in the compounding area. It is also about how the pharmacy works with your team.

Look for a partner that provides:

• A direct point of contact for clinic staff
• Clear prescription intake procedures
• Timely responses to questions
• Refill and renewal reminders
• Transparent turnaround times
• Shipment tracking and storage guidance
• Prompt notification of delays, recalls, or product concerns
• Pharmacist access for formulation and administration questions
• Clear instructions for adverse-event or product-defect reporting

A strong workflow can reduce interruptions for veterinary staff and make it easier for caregivers to stay on schedule.

This is particularly valuable for chronic-care patients receiving long-term treatment for pain, thyroid disease, kidney disease, cardiac conditions, or behavioral concerns. When medications are easier to administer and refills are predictable, caregivers may be more likely to continue treatment as directed.

Consider how compounding supports client loyalty

Chronic-care medicine is built on continuity. A pet may require medication for months or years, with regular monitoring, dose adjustments, and refill coordination.

A compounding partner can help your clinic create a more consistent care experience by supporting:

• Patient-specific dosing
• Easier-to-administer formulations
• Reliable refill cycles
• Medication changes as the patient’s condition evolves
• Better communication between the veterinary team, pharmacy, and caregiver

That consistency can strengthen client trust. When caregivers see that your clinic is focused on finding a workable treatment plan: not simply prescribing a standard product: they may be more likely to remain engaged with the practice and follow through with ongoing care.

For clinics, this can also support recurring chronic-care services and refill-based workflows. The priority should always be the patient’s medical need, but efficient medication support can benefit both patient outcomes and practice operations.

A practical partner-selection checklist

Before choosing a veterinary compounding partner, ask:

1. Is the pharmacy properly licensed for the services and jurisdictions it supports?
2. Does it understand GFI #256 and the August 2026 draft GFI #256B?
3. Can it distinguish patient-specific prescriptions from office stock?
4. Does it offer the dosage forms your patients need?
5. Are ingredients sourced from qualified, licensed suppliers?
6. Are COAs or batch testing documents available?
7. Is beyond-use dating supported by stability information?
8. What controls are used for nonsterile and sterile preparations?
9. Is PCAB accreditation current, if applicable?
10. How does the pharmacy communicate delays, defects, recalls, or adverse events?
11. Can your staff speak with a pharmacist when questions arise?
12. Does the pharmacy have the capacity to support recurring chronic-care volume?

Partner with One Pharmacy

Choosing a compounding pharmacy is a clinical, operational, and quality decision. The right partner should make it easier for your team to prescribe appropriate formulations, support medication compliance, manage chronic-care patients, and maintain clear documentation.

One Pharmacy is ready to discuss how a veterinary compounding partnership can support your clinic’s needs, from custom doses and flavored formulations to transdermal options, refill coordination, and office-stock questions.

Contact One Pharmacy to start a conversation about veterinary compounding support for your clinic or hospital.